Latest Impairment News

DroneShield has locked in $23.2 million in European military contracts and launched RfAI-3, its advanced RF detection engine, while upgrading FY2026 revenue guidance to $250-$270 million.

Yowie Group has doubled its half-year profit to US$0.9 million amid a 16% revenue decline, driven by a US customer range cut and elevated cocoa costs impacting Australia. The confectionery maker advances its turnaround with new product launches and legal wins, while navigating ongoing funding and legacy loan challenges.

Corporate Travel Management (ASX:CTD) has appointed Ana Pedersen as its permanent Managing Director and Group CEO, cementing leadership stability after a challenging period. Pedersen’s extensive industry experience and prior acting CEO tenure position her to steer CTM’s recovery and future growth.

Energy World Corporation is progressing on its US$350 million turbine sale to Hallador Energy with equipment packing underway and funds partially received. The company is also refining its Pagbilao LNG terminal strategy while facing challenges in divesting Australian assets.

Atturra reports FY26 underlying EBITDA in line with guidance despite softer revenue and announces a significant non-cash goodwill impairment tied to government contracts. The company plans substantial FY27 investment in AI, ERP, and education technology to drive organic growth.

Biotron has received pivotal regulatory feedback from the European Medicines Agency ruling out a Hybrid Marketing Authorisation for SedRx, prompting plans for pivotal clinical trials. The company also advances its lead antiviral candidate BIT-HBV001 against Hepatitis Delta Virus and appoints a new chairman.

Actinogen Medical’s phase 2 trial of Xanamem in major depressive disorder with cognitive impairment reveals meaningful antidepressant effects, published in the British Journal of Psychiatry. The drug was safe and well-tolerated but did not improve cognition.

Entropy Neurodynamics has expanded its global intellectual property portfolio with a South African patent for psilocybin-based fibromyalgia treatment, covering broad therapeutic methods and extending protection to 2043.

BHP delivered record iron ore volumes and stable copper production of around 2 million tonnes in FY26, underpinned by disciplined cost control and a robust growth pipeline including the Ministers North project.

Biotron Limited has met the first milestone in its Sedarex acquisition by securing pivotal regulatory feedback from the European Medicines Agency, charting a clearer path for its next-generation anaesthetic SedRx.

Adairs posts 3.7% sales growth in FY26 but underlying EBIT dips 1.3%, weighed down by Focus on Furniture's ongoing struggles and a substantial non-cash impairment.

Frasers Group has escalated its takeover tussle for Accent Group by applying to the Takeovers Panel, disputing Accent’s claims that the offer undervalues the company and seeking orders for additional disclosure or an independent expert review.